Tratamento do mieloma múltiplo com VMCP: revisão de 52 casos
DOI:
https://doi.org/10.32635/2176-9745.RBC.1994v40n4.3005Keywords:
Multiple Myeloma, Chemotherapy, Prognostic FactorsAbstract
Fifty-two patients were treated for multiple myeloma between November 1987andAugust 1992 at the Santa Casa de Misericórdia de Belo Horizonte General Hospital with VMCP (vincristine, melphalan, cyclophosphamide and prednisone) every28 days. Twenty-six patients with bone lesions received palliative radiotherapy. Fifteen (28.8%) were stage IIIA; 32 (61.5%) stage IIIB; five (7.6%) stage I and II by the Salmon and Durie staging system, as used by the SWOG. The response criteria used, when available, was also the proposed by SWOG. Seven patients reached the complete remission, 12 partial remission, 20had stable disease and 13 had progressiva disease. The overall survival was 41 months. Toxicity was well tolerated in the majority of the group. Grade 3-4 toxicity was reached at least once in 30.8%. Three patients died of neutropenic sepsis and 1 of gastrointestinal toxicity. Eight patients are lost of follow-up. The authors considered the actual regimen safe and with satisfactory results.
Downloads
References
ALEXANIAN R, SALMON S, BONNET J et al. Combination therapy for multiple myeloma. Cancer 1977; 49: 2765. DOI: https://doi.org/10.1002/1097-0142(197712)40:6<2765::AID-CNCR2820400602>3.0.CO;2-X
BARTL R, FRISCH B, FATEH-MOGHADAM A, KETTNER G, SOMMERFIELDW. Histologic classification and staging of multiple myeloma: a retrospective and prospective study of 674 cases. Am JClin Pathol1987; 87: 342. DOI: https://doi.org/10.1093/ajcp/87.3.342
BERGSAGEL DE. Myeloma, melphalan and meta-analysis (Editorial). J Clin Oncol 1992; 10(2): 178. DOI: https://doi.org/10.1200/JCO.1992.10.2.178
BERGSAGELDE.Chemotherapyofmyeloma: Drug combinations versus single agents, an overview, and comments on acute leucemia in myeloma. Hematol Oncol 1988; 6; 159. DOI: https://doi.org/10.1002/hon.2900060216
BLADÉ J, SAN MIGUEL JF, ALCAL4 A et al. Alternating combination VMCP/VBAP chemotherapy versus melphalan/prednisone in treatment of multiple myeloma: a randomized multicentric study of 487 cases. J Clin Oncol 1993; 11; 1165. DOI: https://doi.org/10.1200/JCO.1993.11.6.1165
BOCCADORO M, MARMONT F, TRIBALTO M et al. Multiple myeloma: VMCPA/BAP alternating combination is not superior to melphalan and prednisone even in high risk patients. J Clin Oncol
; 9(3): 444.
BOCCADORO M, PILERI A. Standard chemotherapy for myelomatosis: an area of great controversy. Hematol/Oncol Clin North Am 1992; 6(2): 371. DOI: https://doi.org/10.1016/S0889-8588(18)30350-2
BRUMINI R e cols. Câncer no Brasil - Dados Histopatológicos de 1976-1980, Campanha Nacional de Combate ao Câncer, Ministério da Saúde, 1982. Rio de Janeiro.
CUZICK J, De STAVOLA BL, COOPER EH et al. Long term prognostic value of serum B2 microglobulin in myelomatosis. Br J Haematol 1990; 75: 506. DOI: https://doi.org/10.1111/j.1365-2141.1990.tb07790.x
CUZICK J, GALTON DAG, PETO R et al. MRO's Workint Party on Leukemia in Adults: Treatment comparisons in the third MRC myelomatosis trial. Br J Cancer 1980; 42: 823. DOI: https://doi.org/10.1038/bjc.1980.329
DURIE BGM. Chemotherapy of Myeloma: SWOG Studies. Hematol Oncol 1988; 6: 141. DOI: https://doi.org/10.1002/hon.2900060214
DURIE BGM, DIXON DO, CARTER S et al. Improved survival duralion with combination chemotherapy indution for multiple myeloma: a SWOG study. J Clin Oncol 1986; 4: 1227. DOI: https://doi.org/10.1200/JCO.1986.4.8.1227
DURIE BGM, SALMON SE. A clinical staging System for multiple myeloma. Correlation of measured myeloma cell with presenting clinical features, response treatment and survival. Câncer 1975; 36: 842. DOI: https://doi.org/10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U
GREGORY WM, RICHARDS MA, MALPAS JS. Combination chemotherapy versus melphalan and prednisone in the treatment of multiple myeloma: an overview of the published trials. J Clin Oncol 1992; 10(2): 334, DOI: https://doi.org/10.1200/JCO.1992.10.2.334
KELLY K, DURIE B, MacLENNAN A. Prognostic factors and staging Systems for multiple myeloma: comparisons between the MRC and the SWOG. Hematol Oncol 1988; 6: 131. DOI: https://doi.org/10.1002/hon.2900060213
KYLE RA. Prognostic factors in multiple myeloma. Hematol Oncol 1988; 6: 125. DOI: https://doi.org/10.1002/hon.2900060212
MacLENNAN ICM, KELLY K, CROCKSON RA, COOPER EH, CUZICK J, CHAPMAN C. Results of the MRC myelomatosis trials for patients entered since 1980. Hematol Oncol 1988; 6: 145. DOI: https://doi.org/10.1002/hon.2900060215
SALMON SE, CASSADY JR. Plasma cell Neoplasms. In: DeVita V, Hellman S, Rosenberg SA. Cancer Principies & Practice of Oncology. 3rd Ed. Philadelphia: JB Lippincott Co, 1989: 1853.
